Ad5-nCoV
AXP000169.2 · Vaccine
- Platform
- human adenovirus 5 (non-replicating)
- Targets
- SARS-CoV-2 S
- Originator
- Beijing Institute of Biotechnology (Academy of Military Medical Sciences)
- Sponsor
- CanSino Biologics
Names
| Name | Type | Source |
|---|---|---|
| Ad5-nCoV | preferred name, code | curator, wikidata |
| Convidecia | brand | wikidata |
| Convidecia Air | brand | wikidata |
| PakVac ambiguous | brand | wikidata |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- replication-defective adenovirus type 5 encoding the SARS-CoV-2 spike
- Transgenes
- SARS-CoV-2 spike
- Route
- intramuscular, inhaled
- Source
- evidence
Cross-references
- Wikidata
- Q96695265
- FDA UNII
- 5AHC3V2UQS
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2020-06-25 | conditional | Convidecia | Limited use in the Chinese military | source |
| NMPA | CN | 2021-02 | conditional | Convidecia | Prevention of COVID-19, general use | source |
| other | XW | 2022-05 | conditional | Convidecia | WHO emergency use listing | source |
| NMPA | CN | 2022-09-04 | conditional | Convidecia Air | Inhaled booster dose against COVID-19 | source |
Clinical trials (18)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05886790 | A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes | Unknown | 2023-05-30 | 2023-12-31 | 450 | COVID-19 | |
| NCT05855408 | Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults | Unknown | Phase 4 | 2023-05-18 | 2024-05-18 | 10000 | COVID-19 |
| NCT05680896 | SARS-CoV-2 Infection Among Healthcare Workers | Unknown | 2023-02-01 | 2023-03-21 | 600 | COVID-19 | |
| NCT05517642 | IH Convidecia as Second Booster Dose Against Breakthrough Infections | Completed | Phase 3 | 2022-09-20 | 2023-05-02 | 540 | COVID-19 |
| NCT05303584 | Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine | Completed | Phase 4 | 2022-04-23 | 2022-06-20 | 362 | COVID-19 |
| NCT05169008 | A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents | Terminated | Phase 3 | 2022-02-25 | 2023-01-13 | 91 | COVID-19 |
| NCT05204589 | Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine | Completed | Phase 3 | 2022-01-22 | 2022-04-01 | 10285 | COVID-19 |
| NCT05124561 | Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) | Withdrawn | Phase 3 | 2021-12-15 | 2022-04-15 | 0 | COVID-19 |
| NCT05293223 | Phase IIB Study of Recombinant Novel Coronavirus Vaccine | Completed | Phase 2 | 2021-10-01 | 2022-11-15 | 88 | COVID-19 Vaccine |
| NCT04952727 | Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults | Completed | Phase 4 | 2021-08-26 | 2021-11-26 | 300 | COVID-19 |
| NCT05043259 | Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine | Completed | Phase 1/2 | 2021-08-14 | 2021-11-01 | 423 | COVID-19 |
| NCT05005156 | Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV | Completed | Phase 2 | 2021-06-24 | 2023-01-13 | 155 | Covid19 |
| NCT04916886 | A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. | Completed | 2021-06-03 | 2022-07-31 | 2021 | COVID-19 | |
| NCT04892459 | Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) | Completed | Phase 4 | 2021-05-25 | 2021-07-25 | 300 | COVID-19 |
| NCT04833101 | Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine | Completed | Phase 4 | 2021-04-07 | 2021-09-18 | 120 | COVID-19 |
| NCT05313646 | Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults | Completed | Phase 4 | 2021-03-08 | 2021-04-08 | 1050 | COVID-19 |
| NCT04552366 | A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults | Completed | Phase 1 | 2020-09-29 | 2020-12-31 | 149 | COVID-19 |
| NCT04341389 | A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) | Completed | Phase 2 | 2020-04-12 | 2020-11-30 | 508 | COVID-19 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41569047 | Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously. | Human vaccines & immunotherapeutics | 2026 | name in title: Ad5-nCoV |
| PMID 41785679 | Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection. | Vaccine | 2026 | name in abstract: Ad5-nCoV |
| PMID 41863180 | Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial. | Vaccine | 2026 | name in abstract: Ad5-nCoV |
| PMID 42464341 | Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination. | Journal of translational medicine | 2026 | cited by trial NCT04892459 |
| PMID 43013717 | Effects of COVID-19 vaccination type and vaccination-infection interval on viral clearance dynamics in Omicron BA.5 patients at Guangzhou Fangcang shelter hospitals: A propensity score matched multicenter retrospective cohort study. | Human vaccines & immunotherapeutics | 2026 | name in abstract: Ad5-nCoV |
| PMID 39765039 | Humoral Immune Response to SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases. | Archives of medical research | 2025 | name in abstract: Ad5-nCoV |
| PMID 39935878 | Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine. | Frontiers in public health | 2025 | name in abstract: Convidecia |
| PMID 40140382 | Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China. | Nature communications | 2025 | name in abstract: Ad5-nCoV |
| PMID 40498774 | Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). | PloS one | 2025 | cited by trial NCT05005156 |
| PMID 40775215 | Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial. | Nature communications | 2025 | cited by trial NCT05886790 |
| PMID 41103414 | Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population. | Frontiers in immunology | 2025 | name in abstract: Ad5-nCoV |
| PMID 37933089 | Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. | Emerging microbes & infections | 2024 | name in abstract: Ad5-nCoV |
| PMID 38219181 | Heterologous COVID-19 vaccines intervention effect on reactogenicity. | JPMA. The Journal of the Pakistan Medical Association | 2024 | name in abstract: Ad5-nCoV |
| PMID 38456703 | SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. | mBio | 2024 | cited by trial NCT05680896 |
| PMID 39482336 | Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial. | NPJ vaccines | 2024 | cited by trial NCT05517642 |
| PMID 36503413 | Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. | Emerging microbes & infections | 2023 | cited by trial NCT05043259 |
| PMID 36888640 | Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia. | PloS one | 2023 | name in abstract: Ad5-nCoV |
| PMID 36898400 | Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. | The Lancet. Respiratory medicine | 2023 | cited by trial NCT05303584 |
| PMID 37202147 | Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials. | The Journal of infectious diseases | 2023 | cited by trial NCT05303584 |
| PMID 37209700 | Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study. | The Lancet. Respiratory medicine | 2023 | name in title: Ad5-nCoV |
| PMID 37352880 | Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial. | The Lancet. Infectious diseases | 2023 | cited by trial NCT05204589 |
| PMID 37360864 | Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial. | The Lancet regional health. Western Pacific | 2023 | cited by trial NCT04952727 |
| PMID 37428653 | Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19. | Human vaccines & immunotherapeutics | 2023 | cited by trial NCT04341389 |
| PMID 37432025 | Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial. | Expert review of vaccines | 2023 | cited by trial NCT04916886 |
| PMID 37449956 | Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination. | Human vaccines & immunotherapeutics | 2023 | name in abstract: Convidecia |
| PMID 37553338 | Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults. | Nature communications | 2023 | name in title: Ad5-nCoV |
| PMID 37736100 | Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study. | Frontiers in immunology | 2023 | name in title: Ad5-nCoV |
| PMID 37868993 | Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. | Frontiers in immunology | 2023 | name in title: Ad5-nCoV |
| PMID 34812213 | [Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine]. | Enfermedades infecciosas y microbiologia clinica | 2022 | name in title: Ad5-nCoV |
| PMID 34953526 | Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. | Lancet (London, England) | 2022 | name in abstract: Ad5-nCoV |
| PMID 35087233 | Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. | Nature medicine | 2022 | cited by trial NCT04892459 |
| PMID 35277439 | Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study. | Neurology | 2022 | name in abstract: Ad5-nCoV |
| PMID 35605625 | Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. | The Lancet. Respiratory medicine | 2022 | cited by trial NCT05043259 |
| PMID 35617368 | Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. | PLoS medicine | 2022 | cited by trial NCT04833101 |
| PMID 35637121 | Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine. | Enfermedades infecciosas y microbiologia clinica (English ed.) | 2022 | name in title: Ad5-nCoV |
| PMID 35943891 | Seizures following COVID-19 vaccination in Mexico: A nationwide observational study. | Epilepsia | 2022 | name in abstract: Ad5-nCoV |
| PMID 35967368 | Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. | Frontiers in immunology | 2022 | name in abstract: Ad5-nCoV |
| PMID 36048417 | Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. | Expert review of vaccines | 2022 | cited by trial NCT05313646 |
| PMID 34324836 | Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. | The Lancet. Infectious diseases | 2021 | cited by trial NCT04552366 |
| PMID 34622311 | Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. | Rheumatology international | 2021 | name in abstract: Ad5-nCoV |
| PMID 32702299 | Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet (London, England) | 2020 | cited by trial NCT04341389 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41555206 | Short-Term Change in IgG Antibody Elicited by Omicron BA.5 Infection and Inhaled Ad5-nCoV Vaccine Among Healthcare Workers. | Immunity, inflammation and disease | 2026 | name in title: Ad5-nCoV |
| PMID 41640352 | Single-Cell Sequencing Reveals Varying Cell-Mediated Immunity Profiles in Individuals With Distinct Antibody Responses Following Ad5-nCoV Booster. | The Journal of infectious diseases | 2026 | name in title: Ad5-nCoV |
| PMID 41847158 | A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants. | Infectious Disease Modelling | 2026 | name in abstract: Ad5-nCoV |
| PMID 41913864 | Association Between COVID-19 Vaccination, Obesity, and Symptom Burden in a Mexican Population: A Retrospective Cross-Sectional Study. | Cureus | 2026 | name in abstract: Ad5-nCoV |
| PMID 39786643 | Globally approved vaccines for COVID-19: a systematic review. | Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] | 2025 | name in abstract: Convidecia |
| PMID 39864283 | Screening for immunodominant epitopes of SARS-CoV-2 based on CD8+ T cell responses from individuals with HLA-A homozygous alleles. | Molecular immunology | 2025 | name in abstract: Ad5-nCoV |
| PMID 40006661 | Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used. | Vaccines | 2025 | name in abstract: Convidecia |
| PMID 40027891 | Safety and immunogenicity of Ad5-nCoV administered intradermally by needle-free injector in rats. | Frontiers in medicine | 2025 | name in title: Ad5-nCoV |
| PMID 40036106 | Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis. | The Indian journal of medical research | 2025 | name in abstract: Convidecia |
| PMID 40112804 | Molecular basis of Ad5-nCoV vaccine-induced immunogenicity. | Structure (London, England : 1993) | 2025 | name in title: Ad5-nCoV |
| PMID 40177579 | Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants. | Acta pharmaceutica Sinica. B | 2025 | name in abstract: Ad5-nCoV |
| PMID 40266233 | Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. | Vaccines | 2025 | name in abstract: Ad5-nCoV |
| PMID 40315818 | Cryo-ET unravels the mystery of Ad5-nCoV vaccines. | Structure (London, England : 1993) | 2025 | name in title: Ad5-nCoV |
| PMID 41081494 | Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine. | Journal of medical virology | 2025 | name in abstract: Ad5-nCoV |
| PMID 41113693 | Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. | International journal of microbiology | 2025 | name in abstract: Ad5-nCoV |
| PMID 41183574 | Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate. | Journal of controlled release : official journal of the Controlled Release Society | 2025 | name in abstract: Ad5-nCoV |
| PMID 41462459 | Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity. | BMC medicine | 2025 | name in abstract: Ad5-nCoV |
| PMID 38250901 | A Potential Association between Abdominal Obesity and the Efficacy of Humoral Immunity Induced by COVID-19 and by the AZD1222, Convidecia, BNT162b2, Sputnik V, and CoronaVac Vaccines. | Vaccines | 2024 | name in title: Convidecia |
| PMID 38296705 | Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model. | Vaccine | 2024 | name in abstract: Ad5-nCoV |
| PMID 38489915 | The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection. | Virology | 2024 | name in abstract: Ad5-nCoV |
| PMID 38528666 | An Outline of the Immunogenic Potential of Progressing SARSCoV- 2 Vaccine Technologies among Children and Adolescents. | Recent patents on biotechnology | 2024 | name in abstract: Ad5-nCoV |
| PMID 38528839 | Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients. | Journal of medical virology | 2024 | name in title: Ad5-nCoV |
| PMID 38543926 | Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial. | Vaccines | 2024 | name in abstract: Ad5-nCoV |
| PMID 38547193 | Impact of COVID-19 vaccination on liver transplant recipients. Experience in a reference center in Mexico. | PloS one | 2024 | name in abstract: Ad5-nCoV |
| PMID 38570727 | Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines. | Genes and immunity | 2024 | name in abstract: Ad5-nCoV |
| PMID 38573914 | Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population. | PloS one | 2024 | name in title: Ad5-nCoV |
| PMID 38629062 | Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein. | Frontiers in immunology | 2024 | name in abstract: Ad5-nCoV |
| PMID 38650361 | Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis. | Journal of medical virology | 2024 | name in abstract: Ad5-nCoV |
| PMID 38932412 | Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6-17 Years: An Immunobridging Trial. | Vaccines | 2024 | name in abstract: Ad5-nCoV |
| PMID 39178194 | A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV. | Emerging microbes & infections | 2024 | name in title: Ad5-nCoV |
| PMID 39234239 | A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China. | Frontiers in immunology | 2024 | name in abstract: Convidecia |
| PMID 39257586 | Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection. | Frontiers in immunology | 2024 | name in abstract: Ad5-nCoV |
| PMID 39328415 | Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19. | Frontiers in immunology | 2024 | name in abstract: Ad5-nCoV |
| PMID 39360715 | Ad5-nCoV boosted vaccine and reinfection-induced memory T/B cell responses and humoral immunity to SARS-CoV-2: based on two prospective cohorts. | Emerging microbes & infections | 2024 | name in title: Ad5-nCoV |
| PMID 39535117 | Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines. | Human vaccines & immunotherapeutics | 2024 | name in title: Ad5-nCoV |
| PMID 39558654 | Erratum to "Evaluation of the Effectiveness and Safety of Sequential Vaccination With Inactivated SARS-CoV-2 Vaccine and Ad5-nCoV Booster in Pediatric Liver Transplant Recipients". | Journal of medical virology | 2024 | name in title: Ad5-nCoV |
| PMID 39635888 | Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study. | Viral immunology | 2024 | name in abstract: Convidecia |
| PMID 39695978 | Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China. | BMC infectious diseases | 2024 | name in title: Ad5-nCoV |
| PMID 39835127 | Single-cell transcriptome atlas of peripheral immune features to Omicron breakthrough infection under booster vaccination strategies. | Frontiers in immunology | 2024 | name in abstract: Ad5-nCoV |
| PMID 36127294 | Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants. | Journal of medical virology | 2023 | name in title: Ad5-nCoV |
| PMID 36602375 | Longevity and Neutralizing Capacity of IgG Antibodies against SARS-CoV-2 Generated by the Application of BNT162b2, AZD1222, Convidecia, Sputnik V, and CoronaVac Vaccines: a Cohort Study in the Mexican Population. | Microbiology spectrum | 2023 | name in title: Convidecia |
| PMID 36603767 | Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees. | Virologica Sinica | 2023 | name in abstract: Ad5-nCoV |
| PMID 36775188 | Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2023 | name in abstract: Ad5-nCoV |
| PMID 36922500 | Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine. | Signal transduction and targeted therapy | 2023 | name in title: Ad5-nCoV |
| PMID 36998173 | Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. | Human vaccines & immunotherapeutics | 2023 | name in abstract: Ad5-nCoV |
| PMID 37002983 | Comparison of the effectiveness of four SARS-COV-2 v accines in Nuevo Leon, Mexico: A test-negative control study. | Atencion primaria | 2023 | name in abstract: Ad5-nCoV |
| PMID 37112754 | Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico. | Vaccines | 2023 | name in abstract: Ad5-nCoV |
| PMID 37120638 | Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273. | Signal transduction and targeted therapy | 2023 | name in title: Ad5-nCoV |
| PMID 37120945 | Handheld NIR-to-NIR Platform for on-site evaluating protective neutralizing antibody against SARS-CoV-2 ancestral strain and Omicron variant after vaccination or infection. | Biosensors & bioelectronics | 2023 | name in abstract: Ad5-nCoV |
| PMID 37124338 | What contributes to the re-positive nucleic acid test results for the omicron variant of SARS-CoV-2 in the shelter cabin hospital in Shanghai, China? | Heliyon | 2023 | name in abstract: Convidecia |
| PMID 37347197 | Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells. | Microbiology spectrum | 2023 | name in abstract: Ad5-nCoV |
| PMID 37400857 | Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection. | BMC medicine | 2023 | name in title: Ad5-nCoV |
| PMID 37501516 | A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov. | Expert review of vaccines | 2023 | name in title: Ad5-nCoV |
| PMID 37615363 | SARS-CoV-2 seroprevalence and vaccine coverage from August to November 2021: A nationally representative survey in Mexico. | Journal of medical virology | 2023 | name in abstract: Ad5-nCoV |
| PMID 37767190 | Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial. | EClinicalMedicine | 2023 | name in abstract: Ad5-nCoV |
| PMID 37886231 | Assessing the real-world effectiveness of five SARS-CoV-2 vaccines in a cohort of Mexican pensioners: a nationwide nested test-negative design study. | Lancet regional health. Americas | 2023 | name in abstract: Ad5-nCoV |
| PMID 38038866 | Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial. | Infectious diseases and therapy | 2023 | name in abstract: Ad5-nCoV |
| PMID 38140219 | The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China. | Vaccines | 2023 | name in title: Convidecia |
| PMID 38257752 | Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8+ T Cell Responses Specific for Epitopes on Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. | Viruses | 2023 | name in title: Ad5-nCoV |
| PMID 34755408 | Covid-19 vaccines and variants of concern: A review. | Reviews in medical virology | 2022 | name in abstract: Ad5-nCoV |
| PMID 34918097 | Heterologous prime-boost strategies for COVID-19 vaccines. | Journal of travel medicine | 2022 | name in abstract: Ad5-nCoV |
| PMID 35062750 | Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study. | Vaccines | 2022 | name in abstract: Convidecia |
| PMID 35094672 | Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. | Emerging microbes & infections | 2022 | name in abstract: Ad5-nCoV |
| PMID 35153354 | [Reply: Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine]. | Enfermedades infecciosas y microbiologia clinica | 2022 | name in title: Ad5-nCoV |
| PMID 35206580 | Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. | International journal of environmental research and public health | 2022 | name in abstract: Ad5-nCoV |
| PMID 35225871 | Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library. | Antibodies (Basel, Switzerland) | 2022 | name in abstract: Convidecia |
| PMID 35335024 | Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers. | Vaccines | 2022 | name in title: Ad5-nCoV |
| PMID 35335032 | Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study. | Vaccines | 2022 | name in title: Ad5-nCoV |
| PMID 35350457 | [Analysis of budgetary impact of COVID-19 vaccination in Latin AmericaAnálise do impacto orçamentário da vacinação contra a COVID-19 na América Latina]. | Revista panamericana de salud publica = Pan American journal of public health | 2022 | name in abstract: Convidecia |
| PMID 35359754 | Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. | Frontiers in public health | 2022 | name in abstract: Ad5-nCoV |
| PMID 35400561 | Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. | Vaccine | 2022 | name in abstract: Convidecia |
| PMID 35478188 | Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. | Signal transduction and targeted therapy | 2022 | name in abstract: Ad5-nCoV |
| PMID 35484064 | Reply: Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine. | Enfermedades infecciosas y microbiologia clinica (English ed.) | 2022 | name in title: Ad5-nCoV |
| PMID 35604772 | mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. | Emerging microbes & infections | 2022 | name in abstract: Ad5-nCoV |
| PMID 35749390 | Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. | PloS one | 2022 | name in title: Ad5-nCoV |
| PMID 35773445 | A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. | Pharmaceutical research | 2022 | name in abstract: Ad5-nCoV |
| PMID 35787610 | Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination. | Signal transduction and targeted therapy | 2022 | name in title: Ad5-nCoV |
| PMID 35813627 | Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review. | Frontiers in endocrinology | 2022 | name in abstract: Convidecia |
| PMID 35818435 | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers. | Acta pharmaceutica Sinica. B | 2022 | name in abstract: Ad5-nCoV |
| PMID 35841212 | Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines. | European journal of neurology | 2022 | name in abstract: Ad5-nCoV |
| PMID 35926505 | Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. | Cell reports. Medicine | 2022 | name in title: Ad5-nCoV |
| PMID 35952506 | COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes. | Epilepsy & behavior : E&B | 2022 | name in abstract: Ad5-nCoV |
| PMID 35979461 | The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China. | Frontiers in public health | 2022 | name in abstract: Ad5-nCoV |
| PMID 35987196 | SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. | Cell reports | 2022 | name in abstract: Ad5-nCoV |
| PMID 36016185 | Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2. | Vaccines | 2022 | name in abstract: Ad5-nCoV |
| PMID 36028456 | Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients. | Vaccine | 2022 | name in abstract: Ad5-nCoV |
| PMID 36049602 | Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. | Clinical immunology (Orlando, Fla.) | 2022 | name in abstract: Ad5-nCoV |
| PMID 36105809 | Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. | Frontiers in immunology | 2022 | name in abstract: Ad5-nCoV |
| PMID 36266697 | Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. | BMC medicine | 2022 | name in title: Ad5-nCoV |
| PMID 36279685 | Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. | Immunology letters | 2022 | name in title: Ad5-nCoV |
| PMID 36679869 | Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review. | Vaccines | 2022 | name in abstract: Ad5-nCoV |
| PMID 33551672 | The COVID-19 puzzle: a global nightmare. | Environment, development and sustainability | 2021 | name in abstract: Ad5-nCoV |
| PMID 33662986 | Development of SARS-CoV-2 vaccines. | Boletin medico del Hospital Infantil de Mexico | 2021 | name in abstract: Ad5-nCoV |
| PMID 33761791 | A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. | Journal of evidence-based integrative medicine | 2021 | name in abstract: Ad5-nCoV |
| PMID 33804914 | Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. | Diagnostics (Basel, Switzerland) | 2021 | name in abstract: Ad5-nCoV |
| PMID 33807818 | SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. | Vaccines | 2021 | name in abstract: Ad5-nCoV |
| PMID 34373443 | Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. | Cell discovery | 2021 | name in title: Ad5-nCoV |
| PMID 34579236 | IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. | Vaccines | 2021 | name in title: Ad5-nCoV |
| PMID 34579284 | Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. | Vaccines | 2021 | name in title: Ad5-nCoV |
| PMID 34696209 | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. | Vaccines | 2021 | name in abstract: Convidecia |
Notes
Convidecia: single-dose recombinant Ad5 encoding the SARS-CoV-2 spike. Approved for limited military use in China on 25 June 2020 and for general use in February 2021; WHO emergency use listing May 2022; emergency authorisations in Mexico, Pakistan, Hungary, Chile, Malaysia, Indonesia and others not all listed here. The nebulised form Convidecia Air is the same construct given by oral inhalation, so it is a route rather than a new program (NMPA booster approval 4 September 2022); 'inhaled' is not a route value in the spec, so the route cell lists intramuscular only.
How to cite
Ad5-nCoV (AXP000169.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000169.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.